> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Advisory Panel to Review Sparks Eye Therapy
- URL: https://www.fdaweb.com/advisory-panel-to-review-sparks-eye-therapy/
- Published: 2017-08-28T12:00:00.000Z
- Updated: 2026-09-14T22:44:10.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5139479

*Federal Register* notice: FDA has announced a 10/12 Cellular, Tissue, and Gene Therapies Advisory Committee meeting. Panel members are scheduled to discuss and make recommendations on the safety and effectiveness of a Spark Therapeutics BLA for voretigene neparvovec, indicated for treating patients with vision loss due to confirmed biallelic RPE65 mutation-associated retinal dystrophy. To view the notice, click [here](https://www.gpo.gov/fdsys/pkg/FR-2017-08-28/pdf/2017-18161.pdf?ref=fdaweb.com).